SecBot SecBot
8-K ·Filed Apr 7, 2026

ABEO

ABEONA THERAPEUTICS INC.
NEUTRAL
Impact 3/10
Horizonmonths Processed7mo ago SEC0001493152-26-015451
8-K context-dependent: Items 5.02, 7.01
Actionable Insight • Neutral

Monitor for potential improvements in financial governance and capital allocation strategy given Goldan's experience with commercial-stage biotechs and capital markets. No immediate trading catalyst, but could support long-term execution.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$4.81
T+0 close · Apr 7, 2026 · via day close
Latest settled
+33.06%
T+60 · $6.40
Vs SPY
+19.79%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 7 $4.81entry
  2. T+1 · 7mo ago +1.25%α −1.29% · $4.87
  3. T+5 · 7mo ago +7.90%α +2.57% · $5.19
  4. T+20 · 7mo ago +23.70%α +13.92% · $5.95
  5. T+60 · 5mo ago +33.06%α +19.79% · $6.40
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Abeona Therapeutics appointed Keith A. Goldan to its Board of Directors and as Chair of the Audit Committee, citing his two decades of financial leadership experience in biotech. The move strengthens governance as the company advances its commercial-stage gene therapy operations.

Key Facts

  • Keith A. Goldan appointed to Board of Directors effective April 1, 2026
  • Goldan also named Chair of the Audit Committee
  • Board expanded from nine to ten members
  • Goldan is independent under Nasdaq rules
  • Compensation includes $50,000 annual cash fee and $150,000 sign-on equity grant

Financial Impact

Minimal immediate financial impact. $150,000 one-time equity grant and $50,000 annual cash fee represent negligible costs for a company with $272M market cap.

operating expensesshare count

Risk Factors

  • New director appointments do not guarantee improved performance
  • Company continues to face commercialization risks with ZEVASKYN as noted in forward-looking statements

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-015451
Exhibit: ex99-1.htm0001493152-26-015451
Document: 0001493152-26-015451-index-headers.html0001493152-26-015451
Document: 0001493152-26-015451-index.html0001493152-26-015451
Document: 0001493152-26-015451.txt0001493152-26-015451

Track record

29 reports on ABEO

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +15.24% at T+20 after the Sep 29, 2026 report. 4 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $2.59 Now $2.60 +0.39% settles Nov 18
  2. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $2.30 Now $2.60 +13.04% settles Nov 17
  3. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $2.29 to $2.42 Now $2.60 +13.54% ▲ +5.68% +6.04% vs SPY
  4. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
  5. Nov 9, 20267d ago 8-K Bearish 6/10 Entry $2.54 to $2.46 Now $2.60 −2.36% ▲ +3.35% +2.98% vs SPY
  6. Nov 9, 20267d ago Press Release Mixed 6/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
  7. Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $4.17 to $2.54 Now $2.60 −37.65% ▼ −39.09% −41.46% vs SPY
  8. Oct 23, 202624d ago SC 13D Bullish 6/10 Entry $4.40 to $4.31 Now $2.60 −40.91% ▼ −2.05% −2.76% vs SPY
  9. Sep 29, 20266w ago Insider Cluster Bearish 4/10 Entry $5.25 to $5.01 Now $2.60 +50.48% ▲ +4.57% +4.75% vs SPY
  10. Sep 18, 20268w ago Press Release Bullish 6/10 Entry $5.57 to $5.67 Now $2.60 −53.32% ▲ +1.80% +0.24% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens in 8h 44m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 7, 2026